Irinotekan Viatris

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotekan Viatris, is a topoisomerase I inhibitor presented as an intravenous solution for intravenous use. It treats metastatic colorectal cancer and colorectal adenocarcinoma in adult patients.

GNH USA supplies Irinotekan Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Irinotekan is indicated for malignant conditions of the colorectal tract, where inhibition of topoisomerase I is a therapeutic strategy.

- Metastatic colorectal cancer: administered as part of combination chemotherapy to prolong survival and control tumor growth. - Colorectal adenocarcinoma: used in patients with advanced disease to reduce tumor burden and improve response rates. - Colorectal cancer (any stage) in combination regimens: incorporated with fluoropyrimidines and oxaliplatin to enhance cytotoxic effect.

Irinotekan may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Diarrhea: frequent, often severe watery stools. - Nausea and vomiting: gastrointestinal upset requiring anti‑emetic support. - Neutropenia: reduced white blood cell count increasing infection risk. - Alopecia: hair loss affecting scalp and body hair.

Serious or Rare Side Effects: - Severe neutropenic sepsis: life‑threatening infection due to profound neutropenia. - Febrile neutropenia: fever accompanying low neutrophil counts. - Acute cholinergic syndrome: abdominal cramping, sweating, and bradycardia.

When using Irinotekan, clinicians should observe several safety measures to minimize risk. - Baseline blood counts: obtain complete blood count before each cycle to monitor hematologic toxicity. - Liver function monitoring: assess hepatic enzymes because SN‑38 metabolism occurs in the liver. - Hydration status: ensure adequate fluid intake to reduce risk of severe diarrhea. - Concomitant medications: avoid drugs that inhibit UGT1A1, which can increase SN‑38 exposure. - Pregnancy and lactation: contraindicated unless benefits outweigh risks; limited data available. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake the solution.

Irinotekan can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong UGT1A1 inhibitors (e.g., atazanavir): may raise SN‑38 levels and increase toxicity. - CYP3A4 inducers (e.g., rifampicin): can reduce SN‑38 formation, lowering antitumor effect. - High‑dose irinotecan with other topoisomerase I inhibitors: additive bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Anticoagulants (warfarin, DOACs): increased bleeding risk due to mucosal damage from diarrhea. - Antimicrobials causing diarrhea (e.g., clindamycin): may exacerbate gastrointestinal toxicity. - Granulocyte colony‑stimulating factors (G‑CSF): may be used to manage neutropenia but require dose adjustments.